CDP6038

BIOLOGICAL4 trials

Sponsors

UCB Pharma

Conditions

ArthritisHealthy VolunteersPharmacokineticsRheumatoid Arthritis

Phase 1

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

CompletedNCT01009242

UCB PharmaArthritis, Rheumatoid Arthritis

Start: 2009-10-31End: 2010-09-30Updated: 2024-11-15

Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects

CompletedNCT01262794

UCB PharmaHealthy Volunteers

Start: 2010-11-30End: 2011-09-30Updated: 2011-09-27

The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males

CompletedNCT01276119

UCB PharmaPharmacokinetics

Start: 2008-09-30End: 2009-10-31Updated: 2012-03-22

Phase 2

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

CompletedNCT01242488

UCB PharmaRheumatoid Arthritis

Start: 2010-11-30End: 2012-06-30Updated: 2024-07-17

Related Papers

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

2014-03-18106 citations